Engaged in diverse basic, translational and clinical research, our faculty routinely publish in prestigious journals and successfully compete for major grants from national funders.
Andrea L, Berg KM, Johnson NJ, Mitchell OJL, Pearce AK, Green A, Elmer J, Huespe IA, Lanspa MJ, Davis GR, Peltan ID, Herman NS, Malhotra R, Bangar MD, Peterson LN, Wadud N, Mayfield H, Vaena M, Valdez P, Howard TE, Loewe MR, Faiver L, Tam J, Halablab SM, Kaviyarasu A, Baram M, Chan V, Crisci T, Rosal N, Ghamande SA, White HD, Anderson B, Dugar S, Mehkri O, Saleem T, Vine J, Lee JH, Norton DL, Gaillard JP, Wachs T, Herbert JT, Krishnamoorthy V, Wardi G, Long MT, Craigova L, DeMasi SC, Shipley K, Khan A, Schnittke N, Hubel K, Crowley CP, Hansen CK, Dodd KW, Choudhury S, March C, Martinez A, Reyes A, Joffe AM, Bui A, Denchev K, Bissell Turpin BD, Fowajuh R, Ward J, Khan A, Chang C, Richieri E, Mirofsky M, Sagardia J, Piezny D, Gira AR, Cunto E, Khan R, Al-Hakim T, Gong MN, Moskowitz A, . (2026) Temperature Control After In-Hospital Cardiac Arrest: Outcomes From the Discover In-Hospital Cardiac Arrest Cohort. Critical care medicine (Jun), 54(6): 1341-1353.
Almeida ND, Prasad S, Madhugiri V, Berger A, Sinha S, Fang M, Gulzar B, Cheruvu HK, Schrand TV, Goulenko V, Podgorsak M, Snyder KV, Lipinski L, Fabiano AJ, Fenstermaker RA, Prasad D. (2026) Outcomes of Gamma Knife radiosurgery for meningiomas overlying the motor cortex. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia (May), 147: 111909.
A phase 3 double-blind study to evaluate the efficacy and safety of oral ozanimod compared to oral fingolimod in children and adolescents with relapsing-remitting multiple sclerosis. Michael Dwyer, III (Co-Investigator). Bristol Myers Squibb. $1,649,376. 6/1/2023-12/1/2032.
Clinical and Translational Sciences Institute. Ram Samudrala (Co-Investigator). National Center for Advancing Translational Sciences. $28,400,000. 1/1/2026-12/1/2032.
CTSA State University of New York at Buffalo. Zackary Falls (Contributor). National Center for Advancing Translational Sciences (NCATS). $29,204,726. 1/1/2025-12/1/2031.
Clinical and Translational Science Award. Core Operations Special Populations. Ralph Benedict (Co-Investigator). NIH. $29,204,726. 1/1/2025-12/1/2031.
CTSA UM1 State University of New York at Buffalo. Bonnie Vest (Other). NIH. 1/1/2025-12/1/2031.
CTSA UM1 State University of New York at Buffalo. Praveen Chandrasekharan (Co-Investigator). NIH/NCATS. $29,204,726. 8/1/2025-7/1/2031.
Efficacy of Continuous Glucose Monitoring Relative to Traditional Self-Monitoring of Blood Glucose in Non-Insulin Treated Adults with Poorly Controlled T2DM. Obinna Ekwunife (Co-Investigator). NIH/NIDDK. $3,998,816. 7/1/2026-6/1/2031.
CTSA UM1 State University of New York at Buffalo. Gabriela Popescu (Co-Investigator). National Center for Advancing Translational Sciences. $3,710,000. 1/1/2025-1/1/2031.
The UB Primary Care Training and Enhancement – Residency Training in Street Medicine. Brian Clemency (Co-Investigator). HRSA. $2,500,000. 9/1/2025-9/1/2030.
Structure and assembly of membrane proteins at tight junctions. Alex Vecchio (Principal Investigator). NIH/NIGMS. $2,166,105. 9/1/2025-8/1/2030.
Revolutionizing Protein Structure Determination with Advanced SWAXS Analysis. Thomas Grant (Principal Investigator). NIH NIGMS. $2,181,805. 8/1/2025-7/1/2030.
Prevention of Postpartum Smoking Relapse and Related Health Consequences by Breastfeeding Promotion. Xiaozhong Wen (Principal Investigator). National Institute of Health/Eunice Kennedy Shriver National Institute of Child Health and Human Development. $3,361,314. 8/1/2025-7/1/2030.
CTSA K12 Program State University of New York at Buffalo. Praveen Chandrasekharan (Co-Investigator). NIH/NCATS. $3,269,012. 6/1/2025-7/1/2030.
Prevention of Postpartum Smoking Relapse and Related Health Consequences through Breastfeeding Promotion. Praveen Chandrasekharan (Co-Principal Investigator). NICHD. $3,841,280. 8/1/2025-7/1/2030.